Pumitamig + Chemotherapy vs. Nivolumab + Chemotherapy in untreated metastatic Gastric, Gastroesophageal, or GEJ

A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Disease Types: Gastrointestinal

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma 

For More Information:

https://clinicaltrials.gov/study/NCT07221149?term=NCT07221149&rank=1